science, research and innovation · 16 – 17 november 2017 ministerial parallel panel science,...

FIRST WHO GLOBAL MINISTERIAL CONFERENCE

ENDING TB IN THE SUSTAINABLE DEVELOPMENT ERA: A MULTISECTORAL RESPONSE WORLD TRADE CENTER

MOSCOW, RUSSIAN FEDERATION 16 – 17 NOVEMBER 2017

MINISTERIAL PARALLEL

PANEL

SCIENCE,

RESEARCH AND

INNOVATION

Prioritized and well-financed

research is needed to enable the

urgent development and swift

adoption of innovative tools and

strategic interventions critical to

the fight against TB.

Moderator: Glenda Gray, CEO and President, South African Medical Research

Council (SAMRC)

Opening address: Anthony Fauci, Director, National Institute of Allergy and Infectious

Diseases (NIAID), National Institutes of Health (NIH)

Panellists:

o Vytenis Andriukaitis, European Commissioner for Health and Food Safety,

European Union

o Jagat Prakash Nadda, Minister of Health and Family Welfare, India

o Yakovleva Tatiana, Deputy Minister of Healthcare, Russian Federation

o Tina Gifty Naa Ayeley Mensah, Deputy Minister of Health, Ghana

o Erica Lessem, Deputy Executive Director, TB Project, Treatment Action Group

(TAG)

Statements by TB Product Development Partnerships:

o Catharina Boehme, CEO, Foundation for Innovative New Diagnostics

o Melvin Spigelman, President and CEO, TB Alliance

o Jacqueline Shea, CEO, Aeras

o Nick Drager, Executive Director, Tuberculosis Vaccine Initiative

FIRST WHO GLOBAL MINISTERIAL CONFERENCE

ENDING TB IN THE SUSTAINABLE DEVELOPMENT ERA: A MULTISECTORAL RESPONSE WORLD TRADE CENTER

MOSCOW, RUSSIAN FEDERATION 16 – 17 NOVEMBER 2017

The European Commission has invested € 267 million to develop innovative tools for Tuberculosis research

The EU One Health Action Plan against Antimicrobial Resistance addresses MDR-TB as a priority

and are examples of partnerships that we build. We need collaboration at global level

Key Actions

SCIENCE, RESEARCH AND INNOVATION

VYTENIS ANDRIUKAITISEUROPEAN COMMISSIONER

FOR HEALTH AND FOOD SAFETY

EUROPEAN COMMISSION

Government of India's Mission to Strengthen Research to Fight TB

Key thematic areas: Diagnostics, Therapeutics, Vaccines

and Implementation Research

National and International collaboration

Private sector collaboration

India TB Research Consortium


JAGAT PRAKASH NADDA, MINISTER HFW

REPUBLIC OF INDIA

Basic science investigations to develop new vaccines, diagnostics and drugs

The inter-country center on clinical trials of new drugs and regimens of chemotherapy, vaccines, diagnostic technologies and systems

Molecular -epidemiological investigation

Key Actions


YAKOVLEVA TATIANA, MINISTRY OF HEALTH

RUSSIAN FEDERATION

Active standing multisectoral group for rapid review and adoption of new innovations, by MOH/ NTP for implementation .

Increase Access to quality assured digital x-ray screening to Vulnerable populations and in health care setting.

Implementation research as core component in rolling out new innovations/interventions.

Key Actions:


TINA MENSAH, DEPUTY MINISTER OF HEALTH

GHANA

‘Accelerating Tuberculosis case detection in

Ghana’

TB / e-Health project

Bringing Digital X-ray Imaging &

Extra Income to 50 Hospitals nationwide

GHANA

In Africa’s most innovative e-Health project

Key Actions


ERICA LESSEM, TREATMENT ACTION GROUP

Create innovative collaborative financing mechanisms to fast-track development and uptake of tools

Invest in TB R&D 0.1% of Gross Expenditure on R&D

Ensure community participation, equity, transparency, accessibility, availability, affordability, quality

A new treatment standard for all TB patients is imminent.

A healthy pipeline shows promise for short, all-oral treatment for all within a few years.

Global investment is needed. Current funding gap significantly delays new treatment options to #EndTB.

Key Actions


MEL SPIGELMAN, PRESIDENT AND CEO

USA/TB ALLIANCE

Game-changing molecular tools adopted in 50% of countries (2017 Out of Step).

Better diagnostic tools and strategies needed to find “missing millions”, enable drug-

resistant treatment and drive elimination.

Global AND local commitment critical for diagnostic introduction and impact.

Key Actions


CATHARINA BOEHME, CEO

CH/FIND

Innovation: We will not end the TB epidemic without a new vaccine

Investment: Rapid success will take sustained global financial support

Inclusion: TB vaccines must feature prominently in any global TB policies and strategies

Key Actions


JACQUI SHEA, CEO

AERAS, USA


TERESA KASAEVA, THE DEPUTY DIRECTOR OF DEPARTMENT FOR

ORGANIZATION OF MEDICAL CARE AND RESORTS , MOH

RUSSIAN FEDERATION

17 November 2017

9:45-11:15


Together

we will

END TB

science, research and innovation · 16 – 17 november 2017 ministerial parallel panel science,...

Documents